FDA: CAR T-Cell Therapies May Increase Risk for Rare Secondary Cancers

Follow Drugslib on

Medically reviewed by Drugs.com.

By Physician’s Briefing Staff HealthDay Reporter

WEDNESDAY, Jan. 24, 2024 -- Citing recent indications that CAR T-cell therapy may cause rare secondary cancers, the U.S. Food and Drug Administration has told pharmaceutical companies to add a boxed warning to their products.

However, FDA spokesperson Carly Kempler told NBC News that despite the new warning, "the overall benefits of these products continue to outweigh their potential risks." Twenty-five reports of rare blood cancers in patients who had received CAR T-cell therapy prompted the agency to add the boxed warning, Kempler said.

In 2017, the first CAR T-cell therapy, Novartis drug Kymriah, was approved by the FDA. Additional therapies have since been approved. The makers of five of these drugs -- Bristol Myers Squibb, for Abecma and Breyanzi; Gilead Sciences' Kite Pharma, for Yescarta; Johnson & Johnson's Carvykti; and Novartis, for Kymriah -- must submit proposed label changes in the next 30 days to note that CAR T-cell therapy can raise the risk for rare blood cancers, the FDA said. If the drugmakers disagree, they can submit a rebuttal explaining why a change is not needed, NBC News reported.

In a statement, a spokesperson for Novartis said the company has not found "sufficient evidence" to support a link between cancer and its treatment. However, the company will work with the FDA to update its label "appropriately," the spokesman said. Spokespersons for Johnson & Johnson and Gilead Sciences also told NBC News that they would work with the agency to update their labels. A spokesperson for Bristol Myers Squibb said the company is evaluating "next steps" following the FDA notice, although it has not seen any cancer cases associated with its treatment.

CAR T-cell treatments are still relatively new, so the FDA has required the makers of these therapies to conduct 15-year follow-up studies to measure the potential risk for secondary cancers.

The FDA "is not saying that every single one of the cases they've reported has clearly shown CAR T has led to this, but more that there may be an association," Matthew Frigault, M.D., clinical director of the Massachusetts General Hospital Cellular Immunotherapy Program in Boston, told NBC News. "This is what the FDA does. They look for a signal."

NBC News Article

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2024-01-25 22:15

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords